将PD-L1表达水平、既往是否接受过以治愈为目的治疗以及ECOG评分作为分层因素。 基线显示,两组均有~89%的患者PD-L1≥1%(TAP score),~43%的患者PD-L1≥10%。 主要终点OS方面,截至2023年2月13日,最短生存随访时间14.5个月,Tiragolumab+阿替利珠单抗组和安慰剂组的中位OS分别为15.7个月和11.1个月(HR=0.70,95...
[19] developed a CT-based radiomics model to predict the PNI in rectal cancer, achieving an AUC of 0.82, which improved to 0.88 by combining the radiomics score with CT-derived T and N categories in the training set. Guo et al. [21] found that among the single-modality models, the ...
A higher ESCC score was associated with better mobility. We also found that the SINS score recommended guidance correlated with management of surgical patients who presented with MSCC within the tertiary centre.doi:10.1093/bjs/znac039.086R. Peris...
Methods:方法 The ESCC patients who received neoadjuvant CF or DCF at 85 Japanese esophageal centers certified by Japan Esophageal Society were retrospectively reviewed. After propensity score (PS) matching, the overall survival (OS) and recurrence free survival (RFS) were compared bet ween CF and D...
战队 参赛者目前未知 赛事介绍 赛事表 01:45SGT 赛事赛程 往期赛事 TongFu 比分 EP06 七月, 2015, 20:30 Newbee.Y 比分 EP06 七月, 2015, 17:30 vol 比分 Newbee.Y06 七月, 2015, 14:15 TongFu 比分 EP06 七月, 2015, 14:15 EP
© 2013-2025 ggscore.com • IS OPERATED BY GAMEAGEVENTURES LLP 80 Sidney Street, Folkestone, Kent, CT19 6HQ 关于项目 条款 广告 合作伙伴 beta zh 04:55 SGT 登录 注册 dota-2 csgo pubg lol overwatch hearthstone 赛事 竞技 新闻 战队 选手 视频...
Key secondary end points included investigator-assessed progression-free survival (PFS), overall response rate, duration of response, OS in patients with a PD-L1 tumor area positivity score of 10% or greater, and safety. Notably, tumor response was assessed per RECIST 1.1 criteria every...
Enrollment was open to patients with a confirmed diagnosis of ESCC, progression during or after first-line treatment, at least 1 measurable lesion, an ECOG score of 0 or 1 prior to randomization, and adequate organ function. Eligible patients were randomized into either the experimental arm where...
If OS in the all-randomized population proved significant, OS in the subset of patients with a PD-L1 combined positive score (CPS) of at least 10% was evaluated sequentially. Additional Data Findings presented at the 2021 ASCO Annual Meeting showed that the survival benefit achieved with tisl...
A total of 997 patients were enrolled, and eligibility requirements were as follows: locally advanced gastric cancer (GC) or GEJ carcinoma and histologically confirmed adenocarcinoma, no previous systemic therapy for locally advanced unresectable or metastatic GC/GEJ cancer, an ECOG performance score of...